TR199802496T2 - Konjestif kalp yetmezligini tedavi için formülasyon. - Google Patents

Konjestif kalp yetmezligini tedavi için formülasyon.

Info

Publication number
TR199802496T2
TR199802496T2 TR1998/02496T TR9802496T TR199802496T2 TR 199802496 T2 TR199802496 T2 TR 199802496T2 TR 1998/02496 T TR1998/02496 T TR 1998/02496T TR 9802496 T TR9802496 T TR 9802496T TR 199802496 T2 TR199802496 T2 TR 199802496T2
Authority
TR
Turkey
Prior art keywords
heart failure
congestive heart
formulation
treatment
delayed release
Prior art date
Application number
TR1998/02496T
Other languages
English (en)
Inventor
L. Mcnay John
Original Assignee
Eli Lilly And Company
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Eli Lilly And Company filed Critical Eli Lilly And Company
Publication of TR199802496T2 publication Critical patent/TR199802496T2/tr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A61K9/0024—Solid, semi-solid or solidifying implants, which are implanted or injected in body tissue
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure

Landscapes

  • Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Cardiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Hospice & Palliative Care (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Dermatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

Bu bulus, konjestif kalp yetmezligini, gecikmeli salinimli oral veya implant bir formülasyon ve gecikmeli salinimli formülasyonlar içindeki etkili dozda
TR1998/02496T 1996-06-06 1997-06-05 Konjestif kalp yetmezligini tedavi için formülasyon. TR199802496T2 (tr)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US65946396A 1996-06-06 1996-06-06

Publications (1)

Publication Number Publication Date
TR199802496T2 true TR199802496T2 (tr) 1999-02-22

Family

ID=24645503

Family Applications (1)

Application Number Title Priority Date Filing Date
TR1998/02496T TR199802496T2 (tr) 1996-06-06 1997-06-05 Konjestif kalp yetmezligini tedavi için formülasyon.

Country Status (17)

Country Link
EP (1) EP0914128A1 (tr)
JP (1) JP2000511906A (tr)
KR (1) KR20000016406A (tr)
CN (1) CN1226166A (tr)
AU (1) AU3233197A (tr)
BR (1) BR9709546A (tr)
CA (1) CA2256720A1 (tr)
CZ (1) CZ397698A3 (tr)
EA (1) EA199900006A1 (tr)
HU (1) HUP0003885A2 (tr)
IL (1) IL126966A0 (tr)
NO (1) NO985695L (tr)
PL (1) PL330637A1 (tr)
TR (1) TR199802496T2 (tr)
WO (1) WO1997046241A1 (tr)
YU (1) YU55998A (tr)
ZA (1) ZA974978B (tr)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE19815411A1 (de) * 1998-04-06 1999-10-07 Solvay Pharm Gmbh Thermogenese stimulierend wirksame Arzneimittel
AU2727400A (en) * 1999-01-29 2000-08-18 Eli Lilly And Company Moxonidine salts
UA67822C2 (uk) * 1999-02-01 2004-07-15 Солвей Фармас'Ютікалс Гмбх Моксонідин для лікування зумовлених інфарктом міокарда уражень серцевого м'яза, спосіб одержання фармацевтичної композиції
EP1894927B1 (en) * 2006-08-31 2010-11-10 Chemagis Ltd. The use of moxonidine salts for purification of moxonidine
KR100812287B1 (ko) * 2007-01-03 2008-03-13 주식회사 챠콜코리아 내면에 반사층을 갖는 신호등 갓

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4323570A (en) * 1978-11-15 1982-04-06 Beiersdorf Aktiengesellschaft Substituted aminopyrimidines
DE3617158C2 (de) * 1986-05-22 1994-10-06 Lohmann Therapie Syst Lts Transdermales Arzneimittel
DE3729299A1 (de) * 1987-09-02 1989-03-23 Beiersdorf Ag Transdermales therapeutisches system
DE3904795C2 (de) * 1989-02-17 2000-10-12 Lilly Pharma Produktion Gmbh & Pharmazeutisches Präparat und dessen Verwendung
DE4325491A1 (de) * 1993-07-29 1995-02-02 Boehringer Ingelheim Kg Verwendung von zentral wirksamen alpha-2-Agonisten zur Hemmung des Postaggressionsstoffwechsels
DE4423177A1 (de) * 1994-07-01 1996-01-04 Kali Chemie Pharma Gmbh Antihyperglykämisch wirksame Arzneimittel
CA2182851A1 (en) * 1995-08-15 1997-02-16 August Masaru Watanabe Method for treating substance abuse withdrawal

Also Published As

Publication number Publication date
EA199900006A1 (ru) 1999-06-24
IL126966A0 (en) 1999-09-22
CN1226166A (zh) 1999-08-18
ZA974978B (en) 1998-12-07
PL330637A1 (en) 1999-05-24
BR9709546A (pt) 1999-08-10
HUP0003885A2 (hu) 2001-04-28
AU3233197A (en) 1998-01-05
NO985695L (no) 1999-02-04
KR20000016406A (ko) 2000-03-25
JP2000511906A (ja) 2000-09-12
CA2256720A1 (en) 1997-12-11
EP0914128A1 (en) 1999-05-12
YU55998A (en) 1999-11-22
CZ397698A3 (cs) 1999-05-12
NO985695D0 (no) 1998-12-04
WO1997046241A1 (en) 1997-12-11

Similar Documents

Publication Publication Date Title
DK0760848T3 (da) Lactobacillusstammer af menneskelig oprindelse, deres sammensætninger og anvendelse deraf
TR199802423T2 (tr) Konsantre antikor terkibi.
TR200101481T2 (tr) Doğal bitkisel zaruri yağlar kullanan kanser tedavi kompozisyonu ve yöntemi.
TR200101103T2 (tr) CGMP PDE-İnhibitörü içeren kontrollu serbest bırakılan farmasötik formülasyonlar
YU60900A (sh) Novi kristalni oblici antivirusnog benzimidazolskog jedinjenja
EE9800223A (et) Fenantridiinid, neid sisaldavad ravimid ja nende kasutamine
BR0314356A (pt) Formulações de liberação retardada para administração oral de um agente terapêutico polipetìdeo e métodos utilizando as mesmas
ATE400577T1 (de) Anellierte dihydropyrane
TR200100054T2 (tr) Paroksetin metansülfonat
TR200100172T2 (tr) Oral katı doz formunda eprosartan içeren biyolojik bakımdan kuvvetlendirilmiş formülasyonlar
AP1424A (en) 2-Phenyl-1-[4-(2-aminoethoxy)-benzyl]-indole in combination with estrogens.
TR200102385T2 (tr) Kendiliğinden çözülür N-benzoil staurosporin kompozisyonları.
TR199900505T2 (tr)
DK0967987T3 (da) Sammensætning til behandling af tumorer indeholdende hajbruskekstrakter og anitneoplastiske stoffer
SE9802937D0 (sv) Novel compounds
EE9900450A (et) Tetrahüdropüridoühendid, neid sisaldav ravim ja nende kasutamine
CA2408541A1 (en) Treating eczema and/or psoriasis
NO983177L (no) Anvendelse av 1-enantiomeren av centkroman til fremstilling av et farmasaytisk preparat for behandling eller profylakse av brystkreft
TR199802496T2 (tr) Konjestif kalp yetmezligini tedavi için formülasyon.
UA32598C2 (uk) Спосіб одержання лікарської форми карбамазепіну
TR200002847T2 (tr) Biçim VI 5, 6-dikloro-2-(izopropilamino) -1-(beta-L-ribofüranosil) -1H-benzimidazol.
TR200002939T2 (tr) Paroksetin maleat
MD980129A (en) Antiherpetic remedy
DE50009821D1 (de) Blondiermittel
ATE232738T1 (de) Kolostrum enthaltende pharmazeutische zusammensetzungen und deren verwendung